Tag Archives: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

1 Guidance 1.1 Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration‑resistant metastatic prostate cancer in adults, only if: their disease has progressed on or after one docetaxel‑containing chemotherapy regimen, and the manufacturer provides abiraterone in accordance with the commercial access arrangement as agreed with NHS England. 1.2 People […]